Analyzing the nuclear and cytoplasm expression levels, we observed a significant increase in XPO-1 expression in the nucleus in cancer (3.24 ± 3.22) and BPH (1.33 ± 0.83) with p < 0.01 (Fig. 1b) and in Gleason scores > 7 when compared to Gleason scores ≤ 7 (5.27 ± 3.24 vs 2.88 ± 3.31, p < 0.001) and 30/49 [61.2 %] vs 16/50 [32 %] cases with high IRS (P < 0.001, Fig. 1c). This evidence concerns the gene XPO1 and benign prostatic hyperplasia.